// App-Quantinova.ai

1629 : Single-centre open label exploratory phase IIb pilot study of exogenous oral Melatonin for the treatment of Nocturia in adults with Parkinson’s disease

Researchers

Presenter

  • A. Batla

Principal Investigators

  • U. Uchiyama

  • S. Simeoni

  • C. Melbourne

  • M. Baldwin

  • L. DeMin

  • G. Gonzales

  • C. Haslam

  • M. Pakzad

  • S. Islam

  • S. Eriksson

  • K. Bhatia

  • J. Panicker

Medical Centers

  • N/A

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Central Nervous System (CNS)

Disease

  • Parkinson's disease

Biomarkers

  • N/A

Drug/Treatment

  • Melatonin

Outcome

  • N/A

Study Design

  • Open Label

Phase

  • II

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved